Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-0595dd-2026-01-16T12:42:41Z",
    "date": "2026-01-16T12:42:41Z",
    "ocid": "ocds-h6vhtk-0595dd",
    "initiationType": "tender",
    "tender": {
        "id": "ocds-h6vhtk-0595dd",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "85100000",
            "description": "Health services"
        },
        "mainProcurementCategory": "services",
        "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). <br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
        "value": {
            "amount": 142512000,
            "currency": "GBP"
        },
        "lots": [
            {
                "id": "1",
                "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London. <br/><br/>The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
                "value": {
                    "amount": 142512000,
                    "currency": "GBP"
                },
                "contractPeriod": {
                    "durationInDays": 3120
                },
                "hasRenewal": false,
                "submissionTerms": {
                    "variantPolicy": "notAllowed"
                },
                "hasOptions": true,
                "options": {
                    "description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
                },
                "status": "cancelled",
                "title": "Lot 1 - London",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality & innovation",
                            "type": "quality",
                            "description": "50"
                        },
                        {
                            "name": "Value",
                            "type": "quality",
                            "description": "2"
                        },
                        {
                            "name": "Integration, Collaboration & Service Sustainability",
                            "type": "quality",
                            "description": "21"
                        },
                        {
                            "name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
                            "type": "quality",
                            "description": "17"
                        },
                        {
                            "name": "Social Value",
                            "type": "quality",
                            "description": "10"
                        },
                        {
                            "name": "Not Applicable",
                            "type": "cost",
                            "description": "0"
                        }
                    ]
                }
            },
            {
                "id": "2",
                "title": "Lot 2 - East of England",
                "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.<br/><br/>The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality & innovation",
                            "type": "quality",
                            "description": "50"
                        },
                        {
                            "name": "Value",
                            "type": "quality",
                            "description": "2"
                        },
                        {
                            "name": "Integration, Collaboration & Service Sustainability",
                            "type": "quality",
                            "description": "21"
                        },
                        {
                            "name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
                            "type": "quality",
                            "description": "17"
                        },
                        {
                            "name": "Social Value",
                            "type": "quality",
                            "description": "10"
                        },
                        {
                            "name": "Not Applicable",
                            "type": "cost",
                            "description": "0"
                        }
                    ]
                },
                "hasOptions": true,
                "options": {
                    "description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
                },
                "status": "cancelled"
            },
            {
                "id": "3",
                "title": "Lot 3: South East",
                "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.<br/><br/>The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality & innovation",
                            "type": "quality",
                            "description": "50"
                        },
                        {
                            "name": "Value",
                            "type": "quality",
                            "description": "2"
                        },
                        {
                            "name": "Integration, Collaboration & Service Sustainability",
                            "type": "quality",
                            "description": "21"
                        },
                        {
                            "name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
                            "type": "quality",
                            "description": "17"
                        },
                        {
                            "name": "Social Value",
                            "type": "quality",
                            "description": "10"
                        },
                        {
                            "name": "Not Applicable",
                            "type": "cost",
                            "description": "0"
                        }
                    ]
                },
                "hasOptions": true,
                "options": {
                    "description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
                },
                "status": "cancelled"
            },
            {
                "id": "4",
                "title": "Lot 4: South West",
                "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.<br/><br/>The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality & innovation",
                            "type": "quality",
                            "description": "50"
                        },
                        {
                            "name": "Value",
                            "type": "quality",
                            "description": "2"
                        },
                        {
                            "name": "Integration, Collaboration & Service Sustainability",
                            "type": "quality",
                            "description": "21"
                        },
                        {
                            "name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
                            "type": "quality",
                            "description": "17"
                        },
                        {
                            "name": "Social Value",
                            "type": "quality",
                            "description": "10"
                        },
                        {
                            "name": "Not Applicable",
                            "type": "cost",
                            "description": "0"
                        }
                    ]
                },
                "hasOptions": true,
                "options": {
                    "description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
                },
                "status": "cancelled"
            },
            {
                "id": "5",
                "title": "Lot 5: Midlands",
                "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.<br/><br/>The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality & innovation",
                            "type": "quality",
                            "description": "50"
                        },
                        {
                            "name": "Value",
                            "type": "quality",
                            "description": "2"
                        },
                        {
                            "name": "Integration, Collaboration & Service Sustainability",
                            "type": "quality",
                            "description": "21"
                        },
                        {
                            "name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
                            "type": "quality",
                            "description": "17"
                        },
                        {
                            "name": "Social Value",
                            "type": "quality",
                            "description": "10"
                        },
                        {
                            "name": "Not Applicable",
                            "type": "cost",
                            "description": "0"
                        }
                    ]
                },
                "hasOptions": true,
                "options": {
                    "description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
                },
                "status": "cancelled"
            },
            {
                "id": "6",
                "title": "Lot 6: North East & Yorkshire",
                "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.<br/><br/>The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality & innovation",
                            "type": "quality",
                            "description": "50"
                        },
                        {
                            "name": "Value",
                            "type": "quality",
                            "description": "2"
                        },
                        {
                            "name": "Integration, Collaboration & Service Sustainability",
                            "type": "quality",
                            "description": "21"
                        },
                        {
                            "name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
                            "type": "quality",
                            "description": "17"
                        },
                        {
                            "name": "Social Value",
                            "type": "quality",
                            "description": "10"
                        },
                        {
                            "name": "Not Applicable",
                            "type": "cost",
                            "description": "0"
                        }
                    ]
                },
                "hasOptions": true,
                "options": {
                    "description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
                },
                "status": "cancelled"
            },
            {
                "id": "7",
                "title": "Lot 7: North West",
                "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.<br/><br/>The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality & innovation",
                            "type": "quality",
                            "description": "50"
                        },
                        {
                            "name": "Value",
                            "type": "quality",
                            "description": "2"
                        },
                        {
                            "name": "Integration, Collaboration & Service Sustainability",
                            "type": "quality",
                            "description": "21"
                        },
                        {
                            "name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
                            "type": "quality",
                            "description": "17"
                        },
                        {
                            "name": "Social Value",
                            "type": "quality",
                            "description": "10"
                        },
                        {
                            "name": "Not Applicable",
                            "type": "cost",
                            "description": "0"
                        }
                    ]
                },
                "hasOptions": true,
                "options": {
                    "description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
                },
                "status": "cancelled"
            }
        ],
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    },
                    {
                        "region": "UKI"
                    }
                ],
                "relatedLot": "1"
            },
            {
                "id": "2",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKH"
                    }
                ],
                "relatedLot": "2"
            },
            {
                "id": "3",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKJ"
                    }
                ],
                "relatedLot": "3"
            },
            {
                "id": "4",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKK"
                    }
                ],
                "relatedLot": "4"
            },
            {
                "id": "5",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKF"
                    },
                    {
                        "region": "UKG"
                    }
                ],
                "relatedLot": "5"
            },
            {
                "id": "6",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKC"
                    },
                    {
                        "region": "UKE"
                    }
                ],
                "relatedLot": "6"
            },
            {
                "id": "7",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKD"
                    }
                ],
                "relatedLot": "7"
            }
        ],
        "submissionMethod": [
            "electronicSubmission",
            "written"
        ],
        "submissionMethodDetails": "https://health-family.force.com/s/Welcome",
        "communication": {
            "atypicalToolUrl": "https://health-family.force.com/s/Welcome"
        },
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure",
        "coveredBy": [
            "GPA"
        ],
        "tenderPeriod": {
            "endDate": "2025-10-13T12:00:00+01:00"
        },
        "submissionTerms": {
            "languages": [
                "en"
            ],
            "bidValidityPeriod": {
                "endDate": "2026-10-13T23:59:59+01:00"
            }
        },
        "awardPeriod": {
            "startDate": "2025-10-13T12:00:00+01:00"
        },
        "bidOpening": {
            "date": "2025-10-13T12:00:00+01:00"
        },
        "hasRecurrence": false
    },
    "parties": [
        {
            "id": "GB-FTS-130973",
            "name": "NHS England",
            "identifier": {
                "legalName": "NHS England"
            },
            "address": {
                "streetAddress": "Wellington House, 133-135 Waterloo Rd",
                "locality": "London",
                "region": "UKJ1",
                "postalCode": "SE1 8UG",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Jessica Gaucher-Thompson",
                "email": "jessica.gaucher-thompson@nhs.net",
                "url": "https://health-family.force.com/s/Welcome"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.england.nhs.uk/",
                "buyerProfile": "https://www.england.nhs.uk/",
                "classifications": [
                    {
                        "id": "BODY_PUBLIC",
                        "scheme": "TED_CA_TYPE",
                        "description": "Body governed by public law"
                    },
                    {
                        "id": "07",
                        "scheme": "COFOG",
                        "description": "Health"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-141301",
            "name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
            "identifier": {
                "legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
            },
            "address": {
                "streetAddress": "Cardinal Square, 10 Nottingham Road",
                "locality": "Derby",
                "postalCode": "DE1 3QT",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ],
            "details": {
                "url": "https://www.ardengemcsu.nhs.uk/"
            }
        },
        {
            "id": "GB-FTS-171595",
            "name": "University College London Hospitals NHS Foundation Trust",
            "identifier": {
                "legalName": "University College London Hospitals NHS Foundation Trust"
            },
            "address": {
                "locality": "London",
                "region": "UKI",
                "postalCode": "NW1 2PG",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-135891",
            "name": "Guy's and St Thomas' NHS Foundation Trust",
            "identifier": {
                "legalName": "Guy's and St Thomas' NHS Foundation Trust"
            },
            "address": {
                "locality": "London",
                "region": "UKI",
                "postalCode": "SE1 9RT",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171596",
            "name": "Barts Health NHS Trust",
            "identifier": {
                "legalName": "Barts Health NHS Trust"
            },
            "address": {
                "locality": "London",
                "region": "UKI",
                "postalCode": "E1 2ES",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171597",
            "name": "The Royal Marsden NHS Foundation Trust",
            "identifier": {
                "legalName": "The Royal Marsden NHS Foundation Trust"
            },
            "address": {
                "locality": "London",
                "region": "UKI",
                "postalCode": "SW3 6JJ",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-10778",
            "name": "Cambridge University Hospitals NHS Foundation Trust",
            "identifier": {
                "legalName": "Cambridge University Hospitals NHS Foundation Trust"
            },
            "address": {
                "locality": "Cambridge",
                "region": "UKH",
                "postalCode": "CB2 0QQ",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171598",
            "name": "Oxford University Hospitals NHS FT",
            "identifier": {
                "legalName": "Oxford University Hospitals NHS FT"
            },
            "address": {
                "locality": "Oxford",
                "region": "UKJ",
                "postalCode": "OX3 9DU",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171599",
            "name": "University Hospitals Southampton",
            "identifier": {
                "legalName": "University Hospitals Southampton"
            },
            "address": {
                "locality": "Southampton",
                "region": "UKJ",
                "postalCode": "SO16 6YD",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-72289",
            "name": "University Hospitals Bristol and Weston NHS Foundation Trust",
            "identifier": {
                "legalName": "University Hospitals Bristol and Weston NHS Foundation Trust"
            },
            "address": {
                "locality": "Bristol",
                "region": "UKK",
                "postalCode": "BS1 3NU",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171600",
            "name": "UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST",
            "identifier": {
                "legalName": "UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST"
            },
            "address": {
                "locality": "Leicester",
                "region": "UKF",
                "postalCode": "LE1 5WW",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171601",
            "name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust",
            "identifier": {
                "legalName": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
            },
            "address": {
                "locality": "Newcastle upon Tyne",
                "region": "UKC",
                "postalCode": "NE1 4LP",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171602",
            "name": "The Christie NHS Foundation Trust",
            "identifier": {
                "legalName": "The Christie NHS Foundation Trust"
            },
            "address": {
                "locality": "Manchester",
                "region": "UKD",
                "postalCode": "M204BX",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-171603",
            "name": "THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST",
            "identifier": {
                "legalName": "THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST"
            },
            "address": {
                "locality": "Wirral",
                "region": "UKD",
                "postalCode": "CH634JY",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-130973",
        "name": "NHS England"
    },
    "language": "en",
    "description": "This is a Provider Selection Regime(PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.<br/><br/>The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by Wednesday 28th January 2026. Representations should be sent to jessica.gaucher-thompson@nhs.net. The award decision-makers are NHS England National Commissioning Group (NCG).<br/><br/>These contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR.<br/><br/>The Key Criteria used for the award:<br/>Quality & innovation: 50%<br/>Value: 2%<br/>Integration, Collaboration & Service Sustainability: 21%<br/>Improving Access, Reducing Health Inequalities and Facilitating Choice: 17%<br/>Social Value: 10%.<br/><br/>The rationale for selecting the provider(s) was based on them meeting all mandatory requirements and achieving the minimum quality threshold set out in the procurement documentation. This decision has been made as per NHS England governance processes, by the National Commissioning Group on 16th December 2025. No conflicts of Interest were identified amongst decision-makers.",
    "awards": [
        {
            "id": "003869-2026-1",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171595",
                    "name": "University College London Hospitals NHS Foundation Trust"
                }
            ]
        },
        {
            "id": "003869-2026-2",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-135891",
                    "name": "Guy's and St Thomas' NHS Foundation Trust"
                }
            ]
        },
        {
            "id": "003869-2026-3",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171596",
                    "name": "Barts Health NHS Trust"
                }
            ]
        },
        {
            "id": "003869-2026-4",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171597",
                    "name": "The Royal Marsden NHS Foundation Trust"
                }
            ]
        },
        {
            "id": "003869-2026-5",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-10778",
                    "name": "Cambridge University Hospitals NHS Foundation Trust"
                }
            ]
        },
        {
            "id": "003869-2026-6",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171598",
                    "name": "Oxford University Hospitals NHS FT"
                }
            ]
        },
        {
            "id": "003869-2026-7",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171599",
                    "name": "University Hospitals Southampton"
                }
            ]
        },
        {
            "id": "003869-2026-8",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-72289",
                    "name": "University Hospitals Bristol and Weston NHS Foundation Trust"
                }
            ]
        },
        {
            "id": "003869-2026-9",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171600",
                    "name": "UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST"
                }
            ]
        },
        {
            "id": "003869-2026-10",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171601",
                    "name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
                }
            ]
        },
        {
            "id": "003869-2026-11",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171602",
                    "name": "The Christie NHS Foundation Trust"
                }
            ]
        },
        {
            "id": "003869-2026-12",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-171603",
                    "name": "THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST"
                }
            ]
        }
    ],
    "contracts": [
        {
            "id": "003869-2026-1",
            "awardID": "003869-2026-1",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-2",
            "awardID": "003869-2026-2",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-3",
            "awardID": "003869-2026-3",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-4",
            "awardID": "003869-2026-4",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-5",
            "awardID": "003869-2026-5",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-6",
            "awardID": "003869-2026-6",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-7",
            "awardID": "003869-2026-7",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-8",
            "awardID": "003869-2026-8",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-9",
            "awardID": "003869-2026-9",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-10",
            "awardID": "003869-2026-10",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-11",
            "awardID": "003869-2026-11",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        },
        {
            "id": "003869-2026-12",
            "awardID": "003869-2026-12",
            "status": "active",
            "value": {
                "amount": 11876000,
                "currency": "GBP"
            },
            "dateSigned": "2025-12-16T00:00:00Z"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "value": 4
            },
            {
                "id": "2",
                "measure": "bids",
                "value": 4
            },
            {
                "id": "3",
                "measure": "bids",
                "value": 4
            },
            {
                "id": "4",
                "measure": "bids",
                "value": 4
            },
            {
                "id": "5",
                "measure": "bids",
                "value": 1
            },
            {
                "id": "6",
                "measure": "bids",
                "value": 2
            },
            {
                "id": "7",
                "measure": "bids",
                "value": 2
            },
            {
                "id": "8",
                "measure": "bids",
                "value": 2
            },
            {
                "id": "9",
                "measure": "bids",
                "value": 3
            },
            {
                "id": "10",
                "measure": "bids",
                "value": 2
            },
            {
                "id": "11",
                "measure": "bids",
                "value": 2
            },
            {
                "id": "12",
                "measure": "bids",
                "value": 2
            }
        ]
    }
}